Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess how safe and effective the drug Lubiprostone is in
people with Multiple Sclerosis (MS)and moderate to severe MS-associated constipation.
Lubiprostone is approved by the FDA for the treatment of two common types of constipation in
adults, chronic idiopathic constipation and irritable bowel syndrome.